Professor Claudio Mauro
Professor Claudio Mauro has been awarded a full economic cost of £2.3M for the quinquennium 2023-28 towards his research in immunometabolism in atherosclerosis.

Professor Claudio Mauro, Professor of Metabolism and Inflammation at the University of Birmingham, has been awarded a Senior Basic Science Research Fellowship valued at £828,000. The College of Medical and Dental Sciences have also made a financial contribution of £380,000. Professor Mauro has a full economic cost of £2.3M for the quinquennium 2023-28 towards his research in immunometabolism in atherosclerosis.

The Senior Basic Science Research Fellowship is a five-year grant provided by the British Heart Foundation set out to fund outstanding individuals with a proven track record of internationally competitive research. The Fellowship can be taken on a part-time employment basis, where appropriate, and there is a possibility of competitive funding renewal for the following five year period. 

Atherosclerosis is a disease underpinned by chronic inflammation, leading to deadly outcomes, namely strokes and infarctions; yet the role of lactate in atherosclerosis remains unexplored. Cardiovascular immunometabolism is currently in its infancy, which we now aim to lead, since it has great promise for therapeutic gain. This study will dig into and exploit athero-immunometabolism. To support this study, we have generated unique tools and performed unbiased screenings that put us in the strongest possible position to deliver ground-breaking discoveries and translational findings, as well as potential new medicines in cardiovascular immunometabolism in the near future.

Professor Claudio Mauro, Professor of Metabolism and Inflammation, University of Birmingham

Professor Mauro will be utilising the funding award towards generating an array of genetic and pharmacological tools to study the role of immunometabolism in atherosclerosis. It will also be used towards understanding immunometabolic pathways impacting on atherosclerotic plaque formation/development in mice, and to further develop a portfolio of new medicines targeting immunometabolic pathways for therapeutic gain.